Press releases
EU and US Regulatory Update – Tykerb/Tyverb® (lapatinib)
GlaxoSmithKline announced today that it has submitted regulatory applications in Europe and the US related to Tykerb/ Tyverb (lapatinib) and its use in combination with trastuzumab to treat patients with HER2 (ErbB2)-positive metastatic breast cancer.
GSK results announcement for Q4 and full year 2011
GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders
GSK joins new global partnership to help defeat ten neglected tropical diseases by 2020
GSK today announced it has joined other global pharmaceutical companies and leading organisations including the WHO, the Bill & Melinda Gates Foundation, the UK Department for International Development and the USAID in a new united effort to support developing countries to defeat neglected tropical diseases.
GSK announces changes to the Board
GlaxoSmithKline plc today announced that at the company’s Annual General Meeting (AGM) in 2013, following nine years of respective service to the GSK Board, Sir Crispin Davis, Sir Robert Wilson and Mr Larry Culp will not stand for re-election to the Board.
GSK responds to the recent court ruling on the COMPAS study in Mendoza, Argentina
GlaxoSmithKline respectfully disagrees with the recent court ruling in favour of the ANMAT on the fine issued to GSK regarding the administrative conduct of the COMPAS study in Mendoza, Argentina.
GSK and Theravance announce initial outcomes from pivotal Phase III studies for once-daily Relovair™* in COPD and asthma
GSK and Theravance, Inc. today announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair™* in patients with COPD and of all but one of the pivotal studies in patients with asthma.
GlaxoSmithKline provides update on divestment of non-core over-the-counter (OTC) brands
Agreement reached to divest brands in USA and Canada to Prestige Brands Holdings, Inc. for £426m ($660m). Process continues for divesting brands outside these markets and global rights for alli.
GSK extends pneumococcal vaccine agreement with GAVI Alliance
GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world's poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries.
GlaxoSmithKline and Human Genome Sciences initiate phase III trial of belimumab (Benlysta®) administered subcutaneously in subjects with systemic lupus erythematosus
GlaxoSmithKline (GSK) and Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced that dosing has been initiated in BLISS-SC, a new Phase III trialto evaluate the efficacy, safety and tolerability of BENLYSTA® (belimumab) administered subcutaneously (SC) once-weekly to autoantibody-positive adults with active systemic lupus erythematosus (SLE).
GSK presents phase lll data for lapatinib at San Antonio breast cancer symposium
Improvement in disease-free survival does not reach statistical significance in study of delayed adjuvant therapy with lapatinib (Tykerb or Tyverb) monotherapy in HER2 positive breast cancer.
